新橋生物 NBP 深 滬
等待開盤 09-24 09:30:00 美东时间
1.53
-0.060
-3.77%
華盛通- 最 高1.59
- 今 開1.58
- 成交量 59.30万股
- 最 低 1.505
- 昨 收 1.59
- 總市值 1.77亿
- 52周最高 6.79
- 市盈率 靜 --
- 換手率 0.51%
- 52周最低 1.46
- 委 比 -83.09%
- 總股本 1.16亿
- 歷史最高 85.40
- 量 比 2.09
- 振 幅 5.35%
- 歷史最低 0.595
- 每 手 1
- 風險率 1.14%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NovaBridge Biosciences H1 2026 Earnings Call: Complete Transcript
NovaBridge Biosciences (NASDAQ:NBP) held its quarterly earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. Access the full call at https...
09-18 19:51
NovaBridge Biosciences to Participate in September Investor Conferences
NovaBridge Biosciences (Nasdaq: NBP), a global biotechnology company, announced that its CEO, Srishti Gupta, MD, MPP, will participate in two investor conferences in September 2026. The Cantor 2026 Global Healthcare Conference will take place on September 10, 2026, at 1:00 PM ET, and the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, at 9:30 AM ET. Both events will feature Fireside Chats and one-on-one meetings. W...
08-27 11:00
美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
HC Wainwright & Co. Reiterates Buy on NovaBridge Biosciences, Maintains $9 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates NovaBridge Biosciences (NASDAQ:NBP) with a Buy and maintains $9 price target.
08-21 00:38
I-Mab Biopharma GAAP EPS of -$0.33
I-Mab Biopharma press release (NBP): 1H GAAP EPS of -$0.33. As of June 30, 2026, the company had cash, cash equivalents, short-term investments, and equity investment at fair value of $215.9 million. ...
08-20 19:06
NovaBridge Biosciences H1 EPS $(0.33) Misses $(0.14) Estimate
NovaBridge Biosciences (NASDAQ:NBP) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.14) by 135.71 percent.
08-20 19:01
NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026
NovaBridge Biosciences (Nasdaq: NBP) will host a webcast on August 20, 2026, at 9:00 AM ET/9:00 PM China Standard Time to discuss its recent corporate progress and financial results for the first half of 2026. The webcast will be accessible via the provided links or the company's website. NovaBridge, a global biotech company, focuses on advancing therapeutic programs in oncology and ophthalmology, including givastomig and VIS-101.
08-13 21:00
NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026
NovaBridge Biosciences announced it will hold its annual general meeting (AGM) on September 8, 2026, at its Shanghai office. Shareholders of record as of July 27, 2026, are entitled to attend and vote. The Company also filed its annual report on Form 20-F with the SEC and provides updates on its pipeline, including givastomig and VIS-101, which are in clinical development for various cancers and retinal diseases. The AGM materials and annual repo...
07-24 21:00
NovaBridge Biosciences Launches 2026 Omnibus Share Incentive Plan
NovaBridge Biosciences ( ($NBP) ) has provided an update. On July 13, 2026, Nov...
07-17 18:28
